Tissue regeneration co Regentis Biomaterials raises $10m

The funds raised will be used to expand the company's clinical use of its innovative cartilage regeneration implant GelrinC.

Regentis Biomaterials Ltd., which develops proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding from new investors Royal DSM, a Dutch life sciences fund, and from Crossroad Fund, Italian giant Generali's Israeli technology fund, as well as from existing investors Medica Venture Partner, SCP Vitalife Partners, and the Technion Investment Opportunities Fund.

Regentis said that the Series C round of financing will be used to establish its European presence and expand its ongoing clinical efforts of GelrinC a biodegradable implant that enhances growth of articular cartilage in damaged knee joints. It is currently an investigational device, and not available for sale in the US, Europe and Israel.

Regentis Biomaterials CEO Dr. Alastair Clemow said, "With this new investment, Regentis is poised to expand its clinical efforts and further demonstrate how GelrinC can regenerate cartilage so patients can return to an active lifestyle."

Regentis's product allows knee cartilage to regenerate so that it fits tightly with surrounding cartilage and underlying bone. It closely restores cartilage to the condition it was in prior to injury. While there are cartilage repair techniques that relieve pain and restore the knee's functionality, the regenerated cartilage resulting from these procedures is different in nature from the native cartilage and is often followed by subsequent surgical procedure.

Regentis Biomaterials is currently conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of GelrinC. Prior pre-clinical studies have successfully demonstrated its ability to regrow cartilage.

Regentis Biomaterials has offices in Or Akiva in Israel and Princeton, New Jersey in the US.

Published by Globes [online], Israel business news - www.globes-online.com - on May 14, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Joseph Papa Perrigo up for sale

The pharmaceutical firm is seeking a merger at a premium on its $20 billion market cap.

Twitter Facebook Linkedin RSS Newsletters גלובס